Walvax Biotechnology Company Description

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China.

Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine.

The company was founded in 2001 and is headquartered in Kunming, China.

Walvax Biotechnology Co., Ltd.

Country	China
Founded	2001
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	2,388
CEO	Wei Yao

Contact Details

Address: No. 395 Kexin Road Kunming, Yunnan Province 650101 China
Phone	86 87 1683 30860
Website	walvax.com

Stock Details

Ticker Symbol	300142
Exchange	Shenzhen Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100000WN2
SIC Code	2836

Key Executives

Name	Position
Wei Yao	President and Director
Shaozhong Dong	Vice Chairman and Vice President
Changxiong Wu	Chief Financial Officer
Yun Yan Wu	Director of Operations
Yu Ran Liu	Board Secretary
Qingtang Duan	Engineering Director